

RECEIVED
CENTRAL FAX CENTER

DEC 04 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1642
Examiner : Brandon J. Fetterolf
Serial No. : 10/740,266
Filed : December 18, 2003
Inventors : Christian Auclair

Customer No.: 035811

Docket No.: 1417-03

Confirmation No.: 2270

Inventors : Valérie Amsellem
: Martial Hervy
: Frédéric Subra
Title : PHARMACEUTICAL COMPOSITION FOR THE
: DIAGNOSIS, PREVENTION OR TREATMENT
: OF A TUMORAL PATHOLOGY COMPRISING
: AN AGENT MODULATING THE
: POLYMERIZATION STATE OF ACTIN

Dated: December 4, 2006

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Certificate of Facsimile


For

Response

I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name of Applicant, Assignee, Applicant's Attorney
or Registered Representative:

DLA Piper US LLP
Customer No. 035811

By: 

Date: December 4, 2006

RECEIVED
CENTRAL FAX CENTERDEC 04 2006
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1642
Examiner : Brandon J. Fetterolf
Serial No. : 10/740,266
Filed : December 18, 2003
Inventors : Christian Auclair
: Valérie Amsellem
: Martial Hervy
: Frédéric Subra
Title : PHARMACEUTICAL COMPOSITION FOR THE
: DIAGNOSIS, PREVENTION OR TREATMENT
: OF A TUMORAL PATHOLOGY COMPRISING
: AN AGENT MODULATING THE
: POLYMERIZATION STATE OF ACTIN

Customer No.: 035811
Docket No.: 1417-03
Confirmation No.: 2270

Dated: December 4, 2006

RESPONSE


Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is in response to the Restriction Requirement mailed November 27, 2006. A one month shortened statutory response period was set by the action. This Response is being filed prior to that deadline, and no fee is believed due. If a fee is due, the Director is authorized to charge deposit account 50-2719.

The Applicants acknowledge the requirement to elect a single disclosed invention for prosecution on the merits. The Applicants hereby elect "a nucleic acid molecule comprising cDNA of a zyxin gene, a fragment thereof or a complementary sequence" as recited in Claim 43. The claims encompassing the elected invention are claims 43-47 and 50.

Respectfully submitted,


Paul Carango
Reg. No. 42,386
Attorney for Applicants

PC/sh
(215) 656-3320

PHIL13799600.1